Siemens Healthineers has been given a "Neutral" rating by UBS AG, with a target price of 53 euros for the stock. Analyst Graham Doyle has highlighted the company's expansion in photon-counting computed tomography (PCCT), with the product pipeline growing from one to three devices, allowing for a wider range of target groups and budgets.
The trading volume reached 152,868 shares, and the stock has shown a modest gain of 0.4 percent for the year 2024. Investors are eagerly awaiting the Q1 2025 balance sheet presentation, which is scheduled for February 6, 2025.
Siemens Healthineers shares on XETRA rose by 1.0 percent to EUR 51.84, indicating a potential upside of 2.24 percent compared to the target price.